March 23, 2020 – 8 AM EDT: The Federal Reserve is committed to using its full range of tools to support households, businesses, and the U.S. economy overall in this challenging time. The coronavirus pandemic is causing tremendous hardship across the United States and around the world. Our nation’s first priority is to care for those afflicted and to limit the further spread of the virus. While great uncertainty remains, it has become clear that our economy will face severe disruptions. Aggressive efforts must be taken across the public and private sectors to limit the losses to jobs and incomes and to promote a swift recovery once the disruptions abate.Continue reading
Category Archives: AZBio News
COVID-19 Update shared by an Arizona Emergency Physician and Legislator
Amish Shah, MD is an emergency physician at Dignity Health and a member of the Arizona House of Representative elected by the people of LD24 – Central Phoenix and South Scottsdale. On Saturday, March 20, 2020, Dr. Shah shared the message below via Facebook. This Facebook post is republished with permission from Dr. Shah. .Continue reading
First Rapid, Point-of-Care and Near-Patient Molecular Test for Detection of Virus that Causes COVID-19
Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test. The test has been designed to operate on any of Cepheid’s more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.
SBA Offers Small Business COVID-19 Emergency Disaster Loans
The U.S. Small Business Administration is offering low-interest federal disaster loans for working capital to Arizona small businesses suffering substantial economic injury as a result of the Coronavirus. Loans are available for for profit and nonprofit businesses.Continue reading
BIO Launches Coronavirus Hub to Facilitate Exchange of Supplies & Services
The new Coronavirus Hub connects those companies that have relevant supplies, capacities, and resources to share, with those companies, researchers, or healthcare providers that need them. The new hub will enable users to post requests for urgently needed items, as well as to post the availability of supplies and capacityContinue reading
Funding Opportunities: National Institute on Aging at NIH
The National Institute on Aging at NIH (NIA) posted six new Funding Opportunity Announcements in February. Check out what’s new.Continue reading
C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium
TUCSON, Ariz., March 19, 2020 — The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has funded a cooperative agreement to establish a Rare Disease Clinical Outcome Assessment (COA) Consortium. The grant (U01FD006882)* was awarded to the Critical Path Institute (C-Path) with the National Organization for Rare Disorders (NORD) as a sub-awardee. The first step taken toward the establishment of the new consortium has been the creation of the Rare Disease Subcommittee within C-Path’s Patient-Reported Outcome (PRO) Consortium. The PRO Consortium will serve as an incubator for the maturation of a pre-competitive, multi-stakeholder consortium within C-Path’s COA Program.Continue reading
Gilead Sciences Update On The Company’s Ongoing Response To COVID-19
Gilead is working closely with global health authorities to respond to the novel coronavirus (COVID-19) outbreak through the appropriate experimental use of the investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS), National Institute of Allergies and Infectious Diseases (NIAID) and Department of Defense (DoD) – CBRN Medical; the China CDC and National Medical Product Administration (NMPA); the World Health Organization (WHO); and individual researchers and clinicians; Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting COVID-19.Continue reading
COVID-19 is Changing the Way We Live and Work. How Do We Cope?
University of Arizona psychologist David Sbarra shares tips for how to take care of your mental health and support children and loved ones in an uncertain time.Continue reading
FDA Grants Plasmology4® “Breakthrough Device Designation” for the Treatment of Multidrug-Refractory Bacteria
On February 12, 2020, Plasmology4®, Inc., a leader in Plasma Medicine, announced that the company’s product has been granted into the U.S. Food and Drug Administration’s (FDA) Breakthrough Devices Program for the treatment of “multidrug-refractory bacterial and/or fungal pathogen bioburden in a wound bed.”Continue reading